These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 16250039)

  • 1. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.
    Combes B; Emerson SS; Flye NL; Munoz SJ; Luketic VA; Mayo MJ; McCashland TM; Zetterman RK; Peters MG; Di Bisceglie AM; Benner KG; Kowdley KV; Carithers RL; Rosoff L; Garcia-Tsao G; Boyer JL; Boyer TD; Martinez EJ; Bass NM; Lake JR; Barnes DS; Bonacini M; Lindsay KL; Mills AS; Markin RS; Rubin R; West AB; Wheeler DE; Contos MJ; Hofmann AF
    Hepatology; 2005 Nov; 42(5):1184-93. PubMed ID: 16250039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.
    Lindor KD; Dickson ER; Jorgensen RA; Anderson ML; Wiesner RH; Gores GJ; Lange SM; Rossi SS; Hofmann AF; Baldus WP
    Hepatology; 1995 Oct; 22(4 Pt 1):1158-62. PubMed ID: 7557866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
    Lee YM; Kaplan MM
    Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis.
    Momah N; Silveira MG; Jorgensen R; Sinakos E; Lindor KD
    Liver Int; 2012 May; 32(5):790-5. PubMed ID: 22136310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
    Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.
    Van Hoogstraten HJ; De Smet MB; Renooij W; Breed JG; Engels LG; Den Ouden-Muller JW; Rijk MC; Smit AM; Zwertbroek R; Hop WC; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Aliment Pharmacol Ther; 1998 Oct; 12(10):965-71. PubMed ID: 9798800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
    Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
    Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
    Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.
    Eriksson LS; Olsson R; Glauman H; Prytz H; Befrits R; Rydén BO; Einarsson K; Lindgren S; Wallerstedt S; Wedén M
    Scand J Gastroenterol; 1997 Feb; 32(2):179-86. PubMed ID: 9051880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone.
    González-Koch A; Brahm J; Antezana C; Smok G; Cumsille MA
    J Hepatol; 1997 Jul; 27(1):143-9. PubMed ID: 9252088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results.
    Kaplan MM; Cheng S; Price LL; Bonis PA
    Hepatology; 2004 Apr; 39(4):915-23. PubMed ID: 15057894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
    Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
    Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
    Batts KP; Jorgensen RA; Dickson ER; Lindor KD
    Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid.
    Kaplan MM; Bonder A; Ruthazer R; Bonis PA
    Dig Dis Sci; 2010 Nov; 55(11):3207-17. PubMed ID: 20559727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
    Leuschner M; Maier KP; Schlichting J; Strahl S; Herrmann G; Dahm HH; Ackermann H; Happ J; Leuschner U
    Gastroenterology; 1999 Oct; 117(4):918-25. PubMed ID: 10500075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.
    Angulo P; Lindor KD; Therneau TM; Jorgensen RA; Malinchoc M; Kamath PS; Dickson ER
    Liver; 1999 Apr; 19(2):115-21. PubMed ID: 10220741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis.
    Leung J; Bonis PA; Kaplan MM
    Clin Gastroenterol Hepatol; 2011 Sep; 9(9):776-80. PubMed ID: 21699802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholic acid for primary biliary cirrhosis.
    Gluud C; Christensen E
    Cochrane Database Syst Rev; 2002; (1):CD000551. PubMed ID: 11869580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.